More about Cu-67 PSMA : it seems bett... - Advanced Prostate...

Advanced Prostate Cancer

22,364 members28,126 posts

More about Cu-67 PSMA : it seems better than Pluvicto (Lutetium) and it looks like experts are pushing it toward first line treatment!

Maxone73 profile image
3 Replies

I have already talked about this but it continues to look promising, so here is an update:

urotoday.com/video-lectures...

in a nutshell, improved Pluvicto:

"the SECuRE trial for PSMA-targeted radiopharmaceutical in prostate cancer showcases a unique design with double PSMA binding sites and a proprietary SAR chelator, enhancing drug delivery and reducing systemic leakage. Utilizing copper 64 for precise imaging and copper 67 for targeted therapy, the trial has shown promising preclinical and early clinical results with significant tumor targeting and low toxicity. Benefits include fewer required doses, improved patient convenience, and scalable production. The trial's success could lead to broader accessibility and potential FDA approval, offering an effective alternative to current therapies with better safety and patient outcomes."

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
3 Replies
TC007 profile image
TC007

improved Pluvicto is urgently required. I am following this as well very eagerly and this really looks promising. Hopefully, this will be taken up by FDA on priority specially looking at the limited options available

j-o-h-n profile image
j-o-h-n

The one thing I admire about you, is that you're an optimist (to the Max).... so -

Good Luck, Good Health and Good Humor.

j-o-h-n

Maxone73 profile image
Maxone73

my own latest update!

healthunlocked.com/advanced...

Not what you're looking for?

You may also like...

Dr. Sartor and Taylor discuss Copper-67 (Cu-67 or 67Cu), the radioligand I am so curious about!

Dr Sartor interviews dr Taylor who is the lead researcher on copper isotopes to be used for...
Maxone73 profile image

PSMA-targered poisoning

https://www.hopkinsmedicine.org/brady-urology-institute/patient-information/books-publications/artic

Update: FDA grants Priority Review for 177Lu-PSMA-617 for patients with metastatic castration-resistant

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for...
GregHouston profile image

Clarity Update: Complete response in first patient ever treated with 2 doses of Cu-67 SAR-bisPSMA at 8GBq

Highlights A complete response, based on Response Evaluation Criteria In Solid Tumours (RECIST...
God_Loves_Me profile image

Prostate cancer has returned, considering experimental therapy (if I can get it).

Had prostate removed December 2015. PSA remained low, nearly undetectable, at quarterly PSA...